PDF(Pubmed)
Abstract：
UNASSIGNED: To examine the relationship between central macular thickness (CMT) measured by optical coherence tomography (OCT) and visual acuity (VA) in patients with center-involving diabetic macular edema (DME) receiving antivascular endothelial growth factor (anti-VEGF) treatment.
UNASSIGNED: Peer-reviewed articles from 2016 to 2020 reporting intravitreal injections of bevacizumab, ranibizumab, or aflibercept that provided data on pretreatment (baseline) and final retinal thickness (CMT) and visual acuity (VA) were identified. The relationship between relative changes was assessed via a linear random-effects regression model controlling for treatment group.
UNASSIGNED: No significant association between the logarithm of the minimum angle of resolution (logMAR) VA and CMT was found in 41 eligible studies evaluating 2667 eyes. The observed effect estimate was a 0.12 increase (95% CI, -0.124 to 2.47) in logMAR VA per 100 µm reduction in CMT after treatment change. There were no significant differences in logMAR VA between the anti-VEGF treatment groups.
UNASSIGNED: There was no statistically significant relationship between the change in logMAR VA and change in CMT as well as no significant effect of the type of anti-VEGF treatment on the change in logMAR VA. Although OCT analysis, including measurements of CMT, will continue to be an integral part of the management of DME, further exploration is needed on additional anatomic factors that might contribute to visual outcomes.
UNASSIGNED: Peer-reviewed articles from 2016 to 2020 reporting intravitreal injections of bevacizumab, ranibizumab, or aflibercept that provided data on pretreatment (baseline) and final retinal thickness (CMT) and visual acuity (VA) were identified. The relationship between relative changes was assessed via a linear random-effects regression model controlling for treatment group.
UNASSIGNED: No significant association between the logarithm of the minimum angle of resolution (logMAR) VA and CMT was found in 41 eligible studies evaluating 2667 eyes. The observed effect estimate was a 0.12 increase (95% CI, -0.124 to 2.47) in logMAR VA per 100 µm reduction in CMT after treatment change. There were no significant differences in logMAR VA between the anti-VEGF treatment groups.
UNASSIGNED: There was no statistically significant relationship between the change in logMAR VA and change in CMT as well as no significant effect of the type of anti-VEGF treatment on the change in logMAR VA. Although OCT analysis, including measurements of CMT, will continue to be an integral part of the management of DME, further exploration is needed on additional anatomic factors that might contribute to visual outcomes.
摘要：
■在接受抗血管内皮生长因子（抗VEGF）治疗的糖尿病性黄斑水肿（DME）患者中，通过光学相干断层扫描（OCT）测量的黄斑中心厚度（CMT）与视力（VA）之间的关系。
■2016年至2020年同行评议的文章报道了玻璃体内注射贝伐单抗，雷珠单抗,确定了提供治疗前(基线)和最终视网膜厚度(CMT)和视敏度(VA)数据的阿柏西普.通过控制治疗组的线性随机效应回归模型评估相对变化之间的关系。
■在41项评估2667只眼睛的合格研究中，最小分辨角（logMAR）VA的对数与CMT之间没有显着关联。观察到的效果估计是治疗改变后CMT每减少100µm，logMARVA增加0.12（95％CI，-0.124至2.47）。抗VEGF治疗组之间的logMARVA没有显著差异。
■logMARVA的变化与CMT的变化之间没有统计学上的显着关系，抗VEGF治疗类型对logMARVA的变化也没有显着影响。虽然OCT分析,包括CMT的测量，将继续成为DME管理的一个组成部分，需要进一步探索可能导致视觉结局的其他解剖因素.
■2016年至2020年同行评议的文章报道了玻璃体内注射贝伐单抗，雷珠单抗,确定了提供治疗前(基线)和最终视网膜厚度(CMT)和视敏度(VA)数据的阿柏西普.通过控制治疗组的线性随机效应回归模型评估相对变化之间的关系。
■在41项评估2667只眼睛的合格研究中，最小分辨角（logMAR）VA的对数与CMT之间没有显着关联。观察到的效果估计是治疗改变后CMT每减少100µm，logMARVA增加0.12（95％CI，-0.124至2.47）。抗VEGF治疗组之间的logMARVA没有显著差异。
■logMARVA的变化与CMT的变化之间没有统计学上的显着关系，抗VEGF治疗类型对logMARVA的变化也没有显着影响。虽然OCT分析,包括CMT的测量，将继续成为DME管理的一个组成部分，需要进一步探索可能导致视觉结局的其他解剖因素.
